About This Calculator
The Semaglutide Titration Calculator is a clinical support tool designed to map out the standard, evidence-based dosing schedules for initiating and escalating semaglutide therapy. It generates a personalized calendar based on the selected product (Wegovy®, Ozempic®, or Rybelsus®) and the patient's start date. The tool's purpose is to simplify treatment planning and enhance patient education by providing clear, step-by-step timelines for dose adjustments.
Outputs Explained
After you input the necessary information, the calculator generates a detailed titration schedule. The output includes:
- Time Period: The phase of treatment, such as "Weeks 1-4" or "Month 2".
- Date Range: The specific start and end dates for each dosing interval.
- Dosage: The prescribed dose strength and frequency (e.g., "0.25 mg once weekly").
- Notes: Key context for each step, such as "Initial dose" or "Maintenance dose".
- Product Summary: Important administration details and missed dose instructions specific to the selected brand.
How to Use the Tool
- Select Semaglutide Product: Choose the specific brand (Wegovy®, Ozempic®, or Rybelsus®) from the dropdown menu. This is essential as each has a unique dosing schedule.
- Enter Titration Start Date: If the patient is new to therapy, select the date they will take their first dose. The tool defaults to the current date.
- Use Current Dose (Optional): If a patient is already on therapy and needs to continue their titration, select their current dose from the second dropdown. You must then enter the date they started that current dose. The calculator will then generate the schedule for the remaining steps.
- Calculate: Click the "Calculate Schedule" button to generate the complete titration timeline.
Dosing Overview
Semaglutide requires a gradual dose escalation to improve gastrointestinal tolerability. The specific schedules are based on prescribing information for each product.
Wegovy® (for weight management)
Administered once weekly, with dose escalation occurring every 4 weeks. The typical schedule is 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg (maintenance dose).
Ozempic® (for type 2 diabetes)
Administered once weekly. After an initial 4 weeks on 0.25 mg, the dose increases to 0.5 mg. Further increases to 1.0 mg and 2.0 mg can be made after at least 4 weeks on the previous dose if additional glycemic control is needed.
Rybelsus® (for type 2 diabetes)
Administered once daily. Therapy starts with 3 mg for 30 days, then increases to 7 mg. The dose may be further increased to 14 mg after at least 30 days on the 7 mg dose if needed.
Switching Between Therapies
Switching between different GLP-1 receptor agonists (like from liraglutide to semaglutide) or between different semaglutide products (e.g., Ozempic® to Rybelsus®) requires careful clinical consideration. There is no universally standardized protocol, and decisions should be based on the specific products, clinical goals, and patient tolerability. Always consult the full prescribing information for each medication or contact the manufacturer for guidance when planning a switch.
Missed Dose Instructions
The guidance for a missed dose varies by product:
- Wegovy® / Ozempic®: If a dose is missed, it should be administered as soon as possible within 5 days. If more than 5 days have passed, the missed dose should be skipped, and the next dose should be taken on the regularly scheduled day.
- Rybelsus®: If a daily dose is missed, the patient should skip the missed dose entirely and resume with the next dose on the following day.
Safety Alerts
Semaglutide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Other serious warnings and precautions include pancreatitis, diabetic retinopathy complications, acute kidney injury, and hypersensitivity reactions. The most common side effects are gastrointestinal, such as nausea, vomiting, and diarrhea. This tool is not a substitute for clinical judgment; review the full prescribing information before use.
Frequently Asked Questions
Why does the schedule start with a low dose?
A gradual dose escalation, or titration, is required to help the body adapt to the medication and to minimize common gastrointestinal side effects like nausea and diarrhea.
Can I skip a dose escalation step or increase the dose faster?
No, you should not deviate from the recommended dosing schedule without consulting a healthcare provider. The schedule is designed for safety and tolerability.
What happens if I enter my current dose into the calculator?
The tool will calculate the remainder of the standard titration schedule, starting from the next dose escalation step. This is useful for patients who have already started therapy.
Does the calculator account for dose reductions due to side effects?
No, the calculator only generates the standard, FDA-approved dose escalation schedule. Any modification, including dose reduction or pausing therapy, must be guided by a qualified healthcare professional.
Why are the titration schedules different for Wegovy® and Ozempic®?
Although they share the same active ingredient, they are approved for different indications (weight management vs. type 2 diabetes) and have different target maintenance doses, leading to distinct titration pathways.
Why is Rybelsus® taken daily while the others are weekly?
Rybelsus® is an oral tablet formulation, while Wegovy® and Ozempic® are subcutaneous injections. The different administration routes and drug formulations necessitate different dosing frequencies.
Is the information from this calculator a substitute for medical advice?
Absolutely not. This tool is for informational and educational purposes only. It should be used to support, not replace, the clinical judgment of a licensed healthcare provider.
What should I do if I experience severe side effects?
Contact your healthcare provider immediately if you experience severe or persistent side effects, such as severe abdominal pain, persistent vomiting, or signs of an allergic reaction.
References
- Wegovy® (semaglutide) injection Prescribing Information. U.S. Food and Drug Administration.
- Ozempic® (semaglutide) injection Prescribing Information. U.S. Food and Drug Administration.
- Rybelsus® (semaglutide) tablets Prescribing Information. U.S. Food and Drug Administration.
- Wegovy® Dosing and Administration. Novo Nordisk.
